FDA Approves Adjuvant Combo for BRAF+ Melanoma FDA Approves Adjuvant Combo for BRAF+ Melanoma

The two targeted therapies, dabrafenib and trametinib, are already approved in combination in the metastatic setting.FDA Approvals
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Hematology-Oncology News Alert Source Type: news